Shareholders meeting

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 06 July 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Annual Report 2025-26 and the Notice of 34th Annual General Meeting Further to the communication dated 11 June 2026 and pursuant to regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Annual Report for the Financial Year 2025-26, including the Notice of Thirty-fourth Annual General Meeting (“34th AGM”), scheduled to be held on Friday, 31 July 2026, at 04:00 P.M. IST through Videoconferencing is enclosed. The Annual Report and the Notice of 34th AGM is available on the Company’s website at https://sunpharma.com/investors-annual-reports-presentations/ and can also be accessed by scanning the QR code. The information about key events for the 34th AGM and Remote E-voting is as follows: Timeline Cut-off date (for voting eligibility) Friday, 24 July 2026 Remote E-voting Begins Monday, 27 July 2026, at 09:00 A.M. IST Remote E-voting Ends Thursday, 30 July 2026, at 05:00 P.M. IST For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Advancing Innovation Globally Sun Pharmaceutical Industries Limited for Better Patient Care. Annual Report 2025-26 What’s Inside Executive Chairman’s Message Corporate Overview Sun Pharma at a Glance 02 Key Performance Indicators 04 Ten Year Financial Highlights 05 Message from the Executive Chairman 06 Message from the Managing Director 10 Board of Directors 14 Leadership Team 16 Statutory Reports Management Discussion and Analysis 18 Board’s Report 46 Corporate Governance Report 81 Business Responsibility and Sustainability Report 104 See page 06 Our strategy remains focused on introducing novel, clinically Financial Statements differentiated therapies that deliver meaningful and lasting benefits Standalone 146 to patients. From a business Consolidated 228 perspective, we continue to balance long-term investments with near- term business priorities. Notice 328 Dilip Shanghvi Executive Chairman To view our Annual Report 2025-26 online, log on to sunpharma.com/investors-annual-reports-presentations/ Advancing Innovation Globally for Better Patient Care. FY26 marked another important step in Sun Pharma’s The year also marked a significant leadership transition evolution as a globally diversified pharmaceutical company. and laid the foundation for the next phase of growth During the year, we continued to strengthen our presence through the announced acquisition of Organon, which across markets while remaining focused on delivering will expand our global footprint and add Women's Health better outcomes for patients worldwide. to our Innovative Medicines portfolio. Supported by sustained investments in research and development, Our Innovative Medicines business reached a new manufacturing excellence, quality systems and digital watermark contributing 22% of consolidated sales, and for capabilities, we continued to build a more resilient and the first time, accounting for a larger share of US revenues balanced organisation. as compared to US generics. The launch of LEQSELVI and UNLOXCYT expanded our portfolio of innovative As we advance innovation globally, our focus remains therapies, while continued momentum across India, clear-to expand access to quality healthcare, address Emerging Markets and Rest of World markets reinforced unmet patient needs and create sustainable value for the strength of our diversified business model. all stakeholders. Sun Pharmaceutical Industries Limited | Annual Report 2025-26 Sun Pharma at a Glance An Innovation-led Global Leadership across Key Pharmaceutical Company Pharmaceutical Markets Sun Pharma is a leading global pharmaceutical We have established strong positions across our key markets through a broad product portfolio, deep customer company with a diversified presence across relationships and consistent execution. Our market leadership innovative medicines, branded generics, reflects the trust placed in our products and capabilities by generics and active pharmaceutical healthcare professionals, patients and partners worldwide. ingredients (APIs). With a strong foundation built on scientific innovation, manufacturing Largest excellence and market leadership, we serve Pharmaceutical company in India* patients across more than 100 countries through a balanced business model that combines global scale with deep market expertise. This mix enables us to deliver Largest generics company in the US market# quality medicines across markets and therapeutic categories. *As per AIOCD AWACS data for 12 months ended March 2026 #Source: IQVIA data for 12 months ended March 2026 Advancing Innovation Globally for Better Patient Care Sun Pharma at a Glance weivrevO etaroproC stropeR yrotutatS stnemetatS laicnaniF Strong Global Presence Backed by Deep Science and Innovation Our diversified geographic footprint enables us to address Innovation remains central to our growth strategy. healthcare needs across developed and emerging markets We continue to invest in research and development to while strengthening business resilience through balanced advance innovative medicines, strengthen our generics revenue streams and market participation. pipeline, and build differentiated products that address unmet patient needs. Our global R&D ecosystem 100+ integrates scientific expertise, clinical development capabilities and technology-driven innovation. Countries served globally 6.1% R&D spend as a percentage of sales in FY26 Emerging market countries with established 6 operations 67% Global R&D centres 2,700+ International revenue contribution with established operations R&D professionals worldwide Diversified Portfolio Addressing Healthcare Needs Manufacturing Excellence at Global Scale Our business spans innovative medicines, branded Our integrated manufacturing network supports a generics, generics, APIs and consumer healthcare wide range of dosage forms and complex product products, enabling us to serve a wide range of therapeutic categories, enabling us to deliver high-quality medicines needs across patient populations and healthcare systems. efficiently and reliably across markets. The breadth of This diversified portfolio provides multiple avenues for our capabilities strengthens supply chain resilience and growth while supporting long-term business stability. supports future growth opportunities. Portfolio Highlights Manufacturing facilities globally • Fast-growing innovative medicines business focused on dermatology, ophthalmology and Multiple Dosage Platforms onco-dermatology Injectables, sprays, ointments, creams, liquids, • Extensive branded generics and generics tablets and capsules portfolio across global markets • Broad API portfolio serving multiple Powered by a Global Workforce therapeutic categories Our people are the driving force behind our innovation, • Consumer healthcare presence across more growth and operational excellence. By fostering a culture than 25 countries of collaboration, scientific curiosity and continuous improvement, we continue to strengthen our ability to deliver better outcomes for patients worldwide. 47,000+ Innovative products in our Innovative Medicines portfolio Employees across the globe 400+ API products across diverse therapeutic segments Sun Pharmaceutical Industries Limited | Annual Report 2025-26 Key Performance Indicators (Consolidated) Total income (` Million) Net profit after minority interest (` Million) R&D investment (` Million) Reserve & surplus (` Million) [Showing first 8,000 characters — download PDF for full document]